deltatrials
Completed PHASE2 NCT00214058

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma

Sponsor: Aventis Pharmaceuticals

Conditions Ovarian Carcinoma Primary Peritoneal Carcinoma
Interventions Carboplatin Docetaxel
Updated 7 times since 2017 Last updated: Nov 15, 2019 Started: Aug 31, 2002 Completion: Feb 28, 2006

Listed as NCT00214058, this PHASE2 trial focuses on Ovarian Carcinoma and Primary Peritoneal Carcinoma and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aventis Pharmaceuticals
  • University of Wisconsin, Madison
Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Madison, United States